- Home
- AGMB vs TCBX Comparison
AGMB vs TCBX Comparison
Compare AGMB & TCBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGMB | TCBX |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.7M | 659.5M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AGMB | TCBX |
|---|---|---|
| Price | $13.29 | $45.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $32.00 | ★ $45.00 |
| AVG Volume (30 Days) | 89.6K | ★ 105.3K |
| Earning Date | 04-23-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.33 |
| EPS | N/A | ★ 1.97 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $29.99 |
| Revenue Next Year | $17.86 | $10.14 |
| P/E Ratio | ★ N/A | $22.99 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.75 | $35.73 |
| 52 Week High | $17.82 | $46.36 |
Technical Indicators
Market Signals| Indicator | AGMB | TCBX |
|---|---|---|
| Relative Strength Index (RSI) | 49.76 | 62.41 |
| Support Level | $9.54 | $36.49 |
| Resistance Level | $14.19 | N/A |
| Average True Range (ATR) | 1.05 | 0.89 |
| MACD | -0.11 | -0.07 |
| Stochastic Oscillator | 29.81 | 61.99 |
Price Performance
Historical ComparisonAbout AGMB AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
About TCBX Third Coast Bancshares Inc.
Third Coast Bancshares Inc is a bank holding company. It focuses on providing commercial banking solutions to small and medium-sized businesses and professionals with operations in its markets. The bank operates twenty branches in the Greater Houston, Dallas-Fort Worth, and Austin-San Antonio markets, one branch in Ballinger, Texas, and one branch in Detroit, Texas. The company operates through one segment, community banking, It generates the majority of its revenue from interest on loans, customer service, and loan fees.